ReNcell® VM Neural Stem Cell Line Models
New human disease model shows function of PINK1 gene in neural degeneration
Billerica, Massachusetts—July 21, 2008—Millipore Corporation, a Life Science leader providing technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today announced the publication of a new discovery derived from its ReNcell VM neural stem cell line. A study published in June in the journal PLoS ONE established the first functional link between the PINK1 gene and neural degeneration.
Certain forms of familial Parkinson’s disease have been previously linked to mutations in the PINK1 gene, but no mechanistic link between the gene and the disease had been established until now. By suppressing the PINK1 gene in neurons derived from the ReNcell VM cell line, scientists in the laboratory of Nicholas Wood at the Institute of Molecular Neuroscience in London showed that loss of PINK1 function resulted in increased programmed cell death, more free radicals, decreased long-term survival of neurons, and other hallmarks of Parkinson’s disease. A convenient source of differentiated neurons, ReNcell VM cells have now shown to be a valuable, physiologically relevant tool for studying Parkinson’s disease.
The ReNcell VM neural stem cell line was developed by ReNeuron Group plc and is now exclusively marketed by Millipore for the use of neurobiologists and stem cell researchers worldwide. The first marketed human neural progenitor line, ReNcell VM cells are able to readily differentiate into all three neural lineages (neurons, astrocytes, and oligodendrocytes). The cell line grows well and maintains its pluripotency in optimized serum-free media, and thus it is ideal for studying differentiation pathways.
Millipore has evolved from a high performance filtration products and services company into a leading provider of tools and services and a key partner of choice for Life Science customers. We’ve transformed ourselves through R&D investment, organic growth, and acquisitions such as Chemicon, Upstate, Linco, Celliance, Newport Bio Systems, NovAseptic AB and MicroSafe. The integrated Millipore offers more innovative technologies and stronger application support to streamline processes and provide consistently reliable results. The expert scientists in our Life Sciences business unit understand the complexity of Life Science research and can support our customers in their most difficult challenges in cell biology, stem cells, protein research, and cell signaling.
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with 6,000 employees in 47 countries worldwide. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.
ADVANCING LIFE SCIENCE TOGETHERTM
Research. Development. Production.
ReNeuron is a leading, UK-based stem cell therapy business. It is applying its novel stem cell platform technologies in the development of groundbreaking stem cell therapies targeting significant unmet or poorly met clinical needs.
ReNeuron has used its proprietary, patented cell expansion technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation. ReNeuron’s clinically tested cell encapsulation technology provides a method of protecting cells when transplanted, as well as reducing or eliminating the host immune response that might otherwise occur post-transplantation.
ReNeuron is filing for approval to commence initial clinical studies with its lead ReN001 stem cell therapy for chronic stroke disability. There are an estimated 50 million stroke survivors worldwide, approximately one-half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of $50 billion in the US. In addition to its stroke program, ReNeuron is developing stem cell therapies for a number of neurodegenerative diseases and other conditions, including Parkinson’s disease, Type 1 diabetes, and diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell products for use in academic and commercial research. ReNeuron’s ReNcell CX and ReNcell VM neural cell lines are marketed worldwide under license by Millipore Corporation.
ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
Millipore Media Contact:
Millipore, Celliance, Chemicon, Upstate, Linco and NovAseptic are registered trademarks and the “M” logo, ADVANCING LIFE SCIENCE TOGETHER and MicroSafe are trademarks of Millipore Corporation. ReNcell is a trademark of ReNeuron Group plc.